NMN and Metabolism Research

What this page covers

This page evaluates human evidence specifically on metabolic outcomes: insulin sensitivity, glucose regulation, HbA1c, lipid markers, body weight, and body composition. It draws on the full trial set covered in detail on NMN Human Clinical Trials, focused here on what those trials showed for metabolism specifically.

The Yoshino 2021 finding, precisely stated

The most-cited positive metabolic finding is from a 10-week trial in 25 postmenopausal women with prediabetes who were overweight or obese: oral NMN increased insulin-stimulated glucose disposal and muscle insulin signaling, measured by the gold-standard hyperinsulinemic-euglycemic clamp technique.[1] This is a real, positive, primary finding — in a specific population, under specific measurement conditions. The same trial did not report a significant change in whole-body glucose tolerance, fasting glucose, HbA1c, or body weight and composition.[1] Generalizing this result to "NMN improves insulin sensitivity" as a blanket claim — for healthy adults, for men, for people with established type 2 diabetes, or for whole-body glucose control rather than the specific muscle-tissue measure this trial captured — goes beyond what a single population-specific trial demonstrated.

Fasting glucose, HbA1c, and lipids: the pooled picture

A 2025 systematic review and meta-analysis pooling 12 randomized trials and 513 participants found that while NMN significantly raised blood NAD+ overall, most clinically relevant metabolic outcomes — including fasting glucose, fasting insulin, HbA1c, HOMA-IR, and lipid profile — were not significantly different between NMN and control groups.[2] The review's own authors flagged risk-of-bias concerns in the majority of included trials (some concerns in 7, high risk in 5) and explicitly cautioned against exaggerating NMN's metabolic benefits based on the current evidence.[2] This is the most comprehensive pooled evidence available on this specific question, and it does not support a general metabolic-improvement claim.

Body weight and specific lipid changes in individual trials

One trial of MIB-626 (a proprietary high-dose NMN formulation) at 2,000 mg/day for 28 days reported statistically significant decreases in body weight, total and non-HDL cholesterol, and diastolic blood pressure versus placebo in overweight/obese middle-aged and older adults.[3] This is a real, positive, industry-funded, single-trial finding at a high dose, not yet independently replicated by another research group, and should be read alongside the pooled meta-analysis above, which found no consistent lipid or metabolic effect across the broader trial set.

What this means

Human metabolic evidence for NMN is genuinely mixed, not a consistent positive signal: one well-conducted trial found a specific, population-limited insulin-sensitivity benefit; pooled analysis across a larger trial set found no significant effect on the metabolic markers most people would consider clinically meaningful (fasting glucose, HbA1c, lipids); and isolated positive findings on weight and lipids come from a single, high-dose, industry-funded trial not yet replicated. This is not evidence that NMN treats or prevents diabetes, obesity, or metabolic disease, and none of the trials reviewed here were designed or powered to test that.

Related reading

For the full trial-by-trial breakdown, see NMN Human Clinical Trials. For the mechanistic connection between NAD+ and energy metabolism, see NAD+, Mitochondria, and Cellular Energy.